Lytix Biopharma ASA (OSL:LYTIX)
Norway · Delayed Price · Currency is NOK 10.80
+0.25 (2.37%)
May 15, 2026, 3:35 PM CET
Lytix Biopharma ASA Company Description
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.
Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials.
The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.
Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
Lytix Biopharma ASA
| Country | Norway |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Oystein Rekdal |
Contact Details
Address: Sandakerveien 138 Oslo Norway |
Stock Details
| Ticker Symbol | LYTIX |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010405780 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oystein Rekdal Ph.D. | Co-Founder and Chief Executive Officer |
| Gjest Breistein M.Sc. | Chief Financial Officer |
| Dr. Mette Husbyn Ph.D. | Chief Technology Officer |
| Dr. Baldur Sveinbjørnsson Ph.D. | Chief Scientific Officer |
| Brent Meadows M.B.A. | CBO |
| Renee Christine Amundsen | Chief Operating Officer |
| Ole Peter Nordby | Head of IR and Communication Manager |
| Jacqueline Earabino | Head of Clinical Operations |
| Dr. Ahmed Bouzidi Ph.D. | Senior Vice President of Business Development |